April 27th 2024
Targeted therapies and immunotherapies across the ovarian, endometrial, and cervical cancers landscape play expanded roles, according to Ritu Salani, MD, MBA.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
NCCN Creates New Guidelines for Rare Gestational Trophoblastic Disease
October 16th 2018The number of women who develop gestational trophoblastic neoplasia during pregnancy is limited, yet physicians believed that a greater understanding of how to manage this disease was necessary. New guidelines were recently issued by the National Comprehensive Cancer Network to help gynecologic oncologists understand how to treat this rare gestational cancer. Generally, the use of single-agent chemotherapy for most patients with low-risk disease is recommended, with the guidelines reserving surgery and combination chemotherapy for patients at high risk of GTN.<sup>1</sup>
Read More
Clinical Implications for Inherited BRCA Mutations Are Explored in Ovarian Cancer
October 16th 2018Douglas A. Levine, MD, has suggested that many cases of ovarian cancer are preventable, especially in the case of women with hereditary mutations that lead to an increased risk for developing the disease.
Read More
IO Combo Shows Potential in Persistent Ovarian Cancer
October 16th 2018Combining the PD-1 checkpoint inhibitor nivolumab with the CTLA-4 checkpoint inhibitor ipilimumab led to superior survival rates compared to treatment with nivolumab alone in patients with persistent or recurrent ovarian cancer, according to findings from the phase II NRG-GY003 trial.
Read More
Immunotherapy Makes Modest Strides in Cervical Cancer
September 27th 2018The landscape for treatment of gynecologic cancer has changed since 2014, however, better therapeutic strategies and better biomarkers are needed in the realm of gynecologic cancers, Bradley J. Monk, MD, said during a recent webinar about meeting unmet clinical needs in cervical cancer.
Read More
Mirvetuximab Soravtansine Plus Bevacizumab Shows Promising Efficacy in Ovarian Cancer
September 17th 2018David O’Malley, MD, lead investigator of the FORWARD II trial, discusses the emerging combination of mirvetuximab soravtansine plus bevacizumab and the evolving treatment landscape in ovarian cancer.
Read More
Adding the combination of venetoclax (Venclexta) and navitoclax (ABT-263) to chemotherapy induced an objective response rate of 66.7% in adults with relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma, according to results from a small phase I study presented at the 2018 SOHO Annual Meeting.
Read More
Dasatinib Application for Pediatric Ph+ ALL Accepted by FDA
August 31st 2018A supplemental biologics license application for dasatinib (Sprycel) for use in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia has been accepted by the FDA.
Read More
Blinatumomab Granted European Approval for Treatment of Pediatric ALL
August 29th 2018Blinatumomab (Blincyto) has been approved by the European Commission for the treatment of pediatric patients with Philadelphia chromosome–negative, CD19-positive B-cell precursor acute lymphoblastic leukemia that is refractory or in relapse after receiving at least 2 prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation
Read More
Updated Guidelines Recommend HPV Test as Adequate Cervical Cancer Screening for Some
August 29th 2018New guidelines issued by the US Preventive Services Task Force recommend that women aged 30 to 65 years who are at average risk for cervical cancer can choose to receive a Pap smear alone every 3 years or screening with the high-risk human papillomavirus test alone or cotesting every 5 years.
Read More
Tisagenlecleucel Granted Approval in Europe for DLBCL, ALL
August 27th 2018Tisagenlecleucel has gained approval from the European Commission as a treatment for adult patients with diffuse large B-cell lymphoma that is relapsed or refractory after 2 or more lines of systemic therapy, or patients up to 25 years of age with B-cell acute lymphoblastic leukemia that is refractory, in relapse posttransplant, or in second or later relapse.
Read More
Results for Combination Bevacizumab Plus Mirvetuximab Soravtansine in Ovarian Cancer
August 23rd 2018David O’Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the results seen so far with the combination of bevacizumab plus mirvetuximab soravtansine, an antibody-drug conjugate, in patients with platinum-resistant ovarian cancer.
Watch
Examining Recent Data With Niraparib, Immunotherapy in Ovarian Cancer
August 22nd 2018Ursula A. Matulonis, MD, lead author of the phase II QUADRA trial, discusses the activity and tolerability of niraparib in patients with heavily pretreated homologous recombinant deficiency-positive ovarian cancer, and other recent data in ovarian cancer.
Read More
Early Signs of Efficacy Seen With Mesothelin CAR T-Cell Therapy
August 17th 2018Mesothelin-targeted chimeric antigen receptor T-cell therapy has shown early evidence of efficacy in a phase I trial of patients with malignant pleural disease and mesothelioma, non–small cell lung cancer, or breast cancer. Additionally, significant responses were seen in patients who went on to receive subsequent PD-1 checkpoint inhibition treatment.
Read More
The combination of apatinib and oral etoposide showed promising efficacy and a manageable safety profile in patients with platinum-resistant or platinum-refractory ovarian cancer, according to findings from the phase II AEROC trial recently published in <em>The Lancet Oncology</em>.
Read More
Large Phase III ATHENA Trial of Rucaparib/Nivolumab Combo in Ovarian Cancer Now Enrolling
August 9th 2018The first patient has been enrolled in the phase III ATHENA trial looking at rucaparib (Rubraca) in combination with nivolumab (Opdivo) in patients with newly diagnosed advanced ovarian cancer, according to Clovis Oncology, the company developing rucaparib.
Read More
Lenvatinib/Pembrolizumab Receives Breakthrough Therapy Designation from FDA for Endometrial Cancer
August 2nd 2018The combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) has been granted a breakthrough therapy designation by the FDA as a treatment for patients with advanced and/or metastatic non–microsatellite instability high/proficient mismatch repair endometrial carcinoma who have progressed after ≥1 prior systemic therapy. This designation will allow for the expedited development and review of the combination in this setting.
Read More
Outlook on the Future of Ovarian and Other Gynecologic Cancers
July 30th 2018Maurie Markman, MD, President of Medicine and Science at the Cancer Treatment Centers of America, discusses where he sees the field of ovarian cancer and other gynecologic cancers headed in the future, based on the research shared at the 2018 ASCO Annual Meeting.
Watch
In an interview with <em>Targeted Oncology</em>, Panagiotis A. Konstantinopoulos, MD, director of Translational Research, Gynecologic Oncology Program at Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School, discussed the findings from the TOPACIO trial for patients with platinum-sensitive ovarian cancer. He also highlights the outlook for immunotherapy in gynecologic cancers and what the next steps are moving forward.
Read More